Nov 14, 2025
GeneFab presented new insights into how advanced bioreactor engineering and integrated perfusion solutions are transforming next-generation cell therapy manufacturing. The presentation highlighted cutting-edge approaches that enable scalable, contamination-controlled production of high-potency CAR-NK cells for clinical applications.
Innovative Bioreactor Design for Robust CAR-NK Expansion
GeneFab shared new data demonstrating how vertical-wheel bioreactors (VWBs) support efficient CAR-NK cell growth across early-stage (100 mL) and mid-scale (3 L) volumes. The unique hydrodynamic design of the VWB platform enables uniform mixing, gentle agitation, and improved nutrient transfer.
Integrated ATF2 Perfusion for Efficient Medium Exchange
The presentation highlighted how ATF2 perfusion technology enhances process control by enabling continuous medium exchange without interrupting culture integrity. This closed, automated perfusion system minimizes contamination risk while supporting high-density CAR-NK expansion through:
Stable nutrient availability
Efficient removal of metabolic waste
Reduced manual intervention and operator variability
Advancing Toward Clinically Relevant Yields
By combining optimized bioreactor design with integrated perfusion strategies, GeneFab demonstrated scalable CAR-NK manufacturing workflows capable of achieving clinically relevant yields of high-potency cell product. These closed-system, phase-appropriate processes position GeneFab as a strong partner for biopharma innovators progressing toward IND-enabling and clinical manufacturing.
For a deeper dive into the data, platform performance, and process design behind GeneFab’s CAR-NK expansion strategies, click the button below to download the complete white paper.